Search Close


Final Results for the Year Ended 30 April 2011

30th June 2011

A Year of Significant Progress

Scancell Holdings plc, (‘Scancell’ or the ‘Company’) the developer of therapeutic cancer vaccines, announces results for the year ended 30 April 2011.

Highlights during the period:

  • Key development milestone reached with lead therapeutic melanoma vaccine SCIB1
    • Phase I/IIa clinical trials commenced 15 June 2010
  • Secured licensing agreements with:
    • The National Institutes of Health (an agency of the United States Department of Health and Human Services); and
    • Cancer Research Technology Ltd (Cancer Research UK's commercialisation and development arm)
  • Entered strategic collaborations with ImmuneRegen BioSciences, Inc and immatics biotechnologies GmbH
  • Loss before tax for the year of £1.72 million (2010: £1.8 million)
  • Cash at year end £1.1 million (not including the net proceeds from the Placing to be announced today)

To be announced today:

  • New lung cancer vaccine, SCIB2 – latest anti-tumour results in animal models provide further validation of ImmunoBody® vaccine technology platform and its commercial potential
  • Placing to raise £1.73 million (before costs) to fund the working capital of the Company
  • Appointment of Richard Goodfellow as Joint Chief Executive Officer

Professor Lindy Durrant, commented:

“We believe that, following completion of the Placing, we will have sufficient funding to complete the Phase I trials of our melanoma treatment and to advance the development of our series of new ImmunoBody® cancer vaccines to the pre-clinical proof of principle stage. After the Phase I clinical trial has been completed, and if the data is positive, the Company will seek to generate revenues from a commercial deal on the ImmunoBody® technology and will continue with the Phase II clinical trial. A successful outcome should present Scancell as an excellent acquisition opportunity with an exit remaining firmly on the agenda following the completion of the Phase II trial, expected early 2013.”

Scancell Holdings Plc
Professor Lindy Durrant/Dr Richard Goodfellow
+ 44 (0)207 245 1100

Hansard Communications
Adam Reynolds/Guy McDougall
+ 44 (0)207 245 1100

Zeus Capital - Nominated Adviser
Ross Andrews/Tom Rowley
+ 44 (0)161 831 1512

View the full results (PDF file opens in a new window)

Webcasts, Interviews and Media Coverage

Vulpes Life Sciences Fund's Martin Diggle discusses Scancell investment

Martin Diggle, co-founder of Vulpes Investment Management which manages the Vulpes Life Sciences Fund, discusses their recent investment into Scancell Holdings PLC (LON:SCLP).

After buying 77.56mln new shares at a price of 5p per share, which was a slight discount to the 5.35p closing price the previous day, the Vulpes Life Sciences Fund will have a 16.67% stake in the company.

Fri, 21 Jun 2019 08:21:00

Scancell welcomes strategic new investor Vulpes Life Sciences Fund

Scancell Holdings PLC (LON:SCLP) CEO Cliff Holloway caught up with Proactive London's Andrew Scott following the announcement they'd raised £3.88mln via a placing with a single new investor to help fund the progression of its lead cancer asset into clinical trials.

The Vulpes Life Sciences Fund will now have a 16.67% stake in the company when the shares are issued next Monday.

Thu, 13 Jun 2019 09:53:00

Scancell raises £3.9mln to advance immunotherapy product pipeline

“At Vulpes we are always searching for overlooked companies that have the ability to make significant advances in medical science, with a view to supporting their development over the long term. We believe Scancell fulfil these criteria perfectly.”

Thu, 13 Jun 2019 06:31:00